Carlsmed announced today that the FDA granted Breakthrough Device designation for its aprevo® technology for treatment of patients with cervical spine disease.
FDA Grants Second Breakthrough Device Designation for Carlsmed Technology Read More »
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced data from two radiolabeling studies that validate the tumor targeting attributes associated with albumin binding by the FHAB technology.
A global research study is now available in Tamarac, Fla., for an investigational treatment to help patients with a history of atrial fibrillation (AFib) decrease their risk of stroke.
Tamarac Seniors Diagnosed with Atrial Fibrillation Join Innovative Research Study Read More »
Merck announced the U.S. Food and Drug Administration has accepted for priority review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy as treatment with definitive intent for newly diagnosed patients with high-risk locally advanced cervical cancer.
Chroma Medicine, Inc., a genomic medicine company pioneering single-dose epigenetic editing therapeutics, presented positive preclinical data demonstrating the potential of its epigenetic editors to produce efficacious, specific, and durable silencing of the hepatitis B virus during the HBV International Meeting 2023, held September 19-23 in Kobe, Japan.
Asieris Pharmaceuticals has announced that the multinational Phase III clinical trial of APL-1702, a novel, non-surgical treatment of cervical high-grade squamous intraepithelial lesions, has met its primary endpoint.
iZafe Group iZafe Group AB is pleased to announce the successful implementation of their medication robot, Dosell, in Spain.
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced a new multi-target collaboration and license agreement with U.S.-based Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.
El destino final del universo sigue siendo un enigma. ¿Cuándo y cómo llegará el universo a su fin? Veamos las teorías actuales sobre el destino último del cosmos y las incógnitas que los científicos están tratando de resolver para descub …
La visión es esencial para casi todas nuestras actividades diarias, de modo que la cirugía láser para los ojos ha emergido como una tecnología revolucionaria que ha cambiado la vida de millones de personas en todo el mundo. Conozcamos en detalle esta innovadora téc …
Visión clara y precisa: La cirugía láser para los ojos revoluciona la óptica Read More »
